Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

EQUITY (Tables)

v3.22.2.2
EQUITY (Tables)
 6 Months Ended
Jun. 30, 2022
Disclosure of classes of share capital [abstract]  
Disclosure of detailed information about composition of share capital [Table Text Block]
   
June 30,
2022
    
December 31,
2021
  
   
Authorized
    
Issued and outstanding
    
Authorized
    
Issued and outstanding
  
                         
Common Shares without par value
  
Unlimited
      
69,695,325
    
Unlimited
      
68,217,894
  
                                 
Disclosure of detailed information about changes in issued and outstanding share capital [Table Text Block]
   
Number of
shares
  
       
Balance as of January 1, 2022
    
68,217,894
  
         
Common Shares issued as a result of options exercised
    
217,368
  
Common Shares issued in settlement of purchase consideration of a business combination (1)
    
1,260,063
  
         
Balance as of June 30, 2022
    
69,695,325
  
 
  (1)
    Pharm Yarok - 523,700, Vironna - 485,362, Oranim - 251,001
Disclosure of detailed information about number and weighted average exercise prices of share options [Table Text Block]
 
   
Six months ended
June 30, 2022
  
   
Number of
options
    
Weighted
average
exercise
price
  
         
in CAD
  
             
Options outstanding at the beginning of the period
    
5,443,245
      
3.91
  
                 
Options granted during the period
    
97,500
      
2.13
  
Options exercised during the period (*)
    
(227,067
)
    
1.60
  
Options forfeited during the period
    
(188,850
)
    
7.63
  
                 
Options outstanding at the end of the period
    
5,124,828
      
3.89
  
                 
Options exercisable at the end of the period
    
2,799,538
      
3.77
  
 
(*) Includes 18,755 Options exercised under cashless mechanism to 9,056 Common Shares.